Back to Search
Start Over
Additional Mutational Events at Diagnosis of CML Confer Inferior Failure-Free Survival and Molecular Response for Patients Treated with Frontline Imatinib but Not for Patients Treated with Frontline Second-Generation Tyrosine Kinase Inhibitors
- Source :
- Blood. 140:805-806
- Publication Year :
- 2022
- Publisher :
- American Society of Hematology, 2022.
- Subjects :
- Immunology
Cell Biology
Hematology
Biochemistry
Subjects
Details
- ISSN :
- 15280020 and 00064971
- Volume :
- 140
- Database :
- OpenAIRE
- Journal :
- Blood
- Accession number :
- edsair.doi...........4890e78602b3ae78fe24ff473f7b8f6c
- Full Text :
- https://doi.org/10.1182/blood-2022-158743